Talk:Evergreening/Archives/2015

I just don't get it

There are good examples of how future evergreening strategies could work. But what do these companies do today?? I think in such a relativly long articel a few examples should be mentioned. --79.210.120.150 (talk) 20:10, 12 February 2015 (UTC)

A potential example

On http://theconversation.com/explainer-evergreening-and-how-big-pharma-keeps-drug-prices-high-33623 there is this example:

"Evergreening is achieved by seeking extra patents on variations of the original drug – new forms of release, new dosages, new combinations or variations, or new forms." Fine. So if these new forms have little or no advantage why can't the generic-manufacter produce the "old" drug? The old patent is not extended by new patens which are built on top of the old one. — Preceding unsigned comment added by 79.210.120.150 (talk) 20:17, 12 February 2015 (UTC)

Maybe this one here?

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680578/

"'And even if they make a modification to a drug, doctors are still quite able to prescribe the generic version of the older product. Having said that, the brand-name companies put an awful lot of money into marketing the newer version, and that marketing is designed to affect what doctors do.'"

So maybe it works this way: The patent is about to expire, the companies patents a new drug which not/only a bit better and than puts a lot of marketing efforts into making doctors prescribe the new and not the old drug. Ok, that could work, but that's something every company could do not just the inventor of the old drug. --79.210.120.150 (talk) 20:26, 12 February 2015 (UTC)

giving a fresh loan to repay an old one

Maybe should also reflect this meaning of evergreening? http://www.ibnlive.com/news/business/banks-should-desist-from-evergreening-of-loans-yashwant-sinha-1001990.html Evergreening refers to the practice of giving a fresh loan to repay an old one — Preceding unsigned comment added by 217.14.40.189 (talk) 10:45, 20 October 2015 (UTC)